Catalent to Commercially Supply Palatin FSD Pen Injectors

Catalent Pharma Solutions and Palatin Technologies have reached a commercial supply agreement to support the launch of Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD), Catalent said in a June 30, 2016 press announcement. Bremelanotide is a subcutaneous injectable peptide melanocortin receptor agonist and is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. The bremelanotide pen injectors will be produced at Catalent's 265,000-sq.-ft. Brussels, Belgium facility, Catalent noted. Phase III trials of bremelanotide are currently ongoing, with launch anticipated in 2018.

Source: Catalent